2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3893
    PSTAIR 126675-53-4 98%
    PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control.
    PSTAIR
  • HY-P3926
    Amylin (8-37) (human) 309244-90-4 98%
    Amylin (8-37) (human) (hIAPP (8-37)) is a 8-37 fragment of human islet amyloid polypeptide (IAPP). The duplex folding structure in the Amylin (8-37) (human) assembly has a hairpin structure.
    Amylin (8-37) (human)
  • HY-P3952
    (D-Trp8,D-Cys14)-Somatostatin-14 61950-59-2 98%
    (D-Trp8,D-Cys14)-Somatostatin-14 is a Somatostatin synthetic analogue. (D-Trp8,D-Cys14)-Somatostatin-14 can be used for the research of metabolic related diseases.
    (D-Trp8,D-Cys14)-Somatostatin-14
  • HY-P3953
    Wy 41747 68463-41-2 98%
    Wy 41747 is a long-acting Somatostatin analogue. Wy 41747 can be used for the research of diabetes mellitus.
    Wy 41747
  • HY-P3955
    RC-160 [Lys(Boc)] 139668-78-3 98%
    RC-160 [Lys(Boc)], a 8-aa peptide, is a Somatostatin analog.
    RC-160 [Lys(Boc)]
  • HY-P3991
    Bradykinin potentiator C 30953-20-9 98%
    Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide.
    Bradykinin potentiator C
  • HY-P4015
    VIP (1-12), human, porcine, rat, ovine 120928-03-2 98%
    VIP (1-12), human, porcine, rat, ovine is a vasoactive intestinal peptide (VIP) fragment. VIP (1-12), human, porcine, rat, ovine is a ligand for the CD4 (T4)/human immunodeficiency virus receptor.
    VIP (1-12), human, porcine, rat, ovine
  • HY-P4040
    Ac-D-DGla-LI-Cha-C 208940-40-3 98%
    Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases.
    Ac-D-DGla-LI-Cha-C
  • HY-P4062
    Insulin peglispro 1200440-65-8 98%
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.
    Insulin peglispro
  • HY-P4063
    Pegylated synthetic human c-peptide 1350661-05-0 98%
    Pegylated synthetic human c-peptide retains bioactivity comparable to that of natural (i.e. non-polyethylene glycolated) C-peptides and has a prolonged circulating residence time in plasma for use in diabetic peripheral neuropathy studies.
    Pegylated synthetic human c-peptide
  • HY-P4110
    TAT-NSF222 Fusion Peptide 98%
    TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor.
    TAT-NSF222 Fusion Peptide
  • HY-P4378
    H-Leu-Gly-βNA 100930-00-5 98%
    H-Leu-Gly-βNA can be used as a substrate to detect the presence or absence of N-acetyl-BD-galactosaminidase.
    H-Leu-Gly-βNA
  • HY-P4381
    γ-Glu-Gly-Gly 13640-39-6 98%
    γ-Glu-Gly-Gly is a tripeptide that can be used as a peptide substrate to generate Glu.
    γ-Glu-Gly-Gly
  • HY-P4386
    (Asp28)-Exenatide 1678417-24-7 98%
    (Asp28)-Exenatide is a degradation product of exenatide (HY-13443). (Asp28)-Exenatide can be used as a GLP-1R agonist.
    (Asp28)-Exenatide
  • HY-P4389
    (Asp28)-Glucagon (1-29) (human, rat, porcine) 1037751-81-7 98%
    (Asp28)-Glucagon (1-29) (human, rat, porcine) is an optimized structure of glucagon, the 28th position is replaced by aspartic acid (Asp) which significantly increases the aqueous solubility of glucagon in a physiological pH buffer, has the same activity as glucagon.
    (Asp28)-Glucagon (1-29) (human, rat, porcine)
  • HY-P4407
    (D-Asn28)-Exenatide 2022972-66-1 98%
    (D-Asn28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist.
    (D-Asn28)-Exenatide
  • HY-P4410
    (D-Asp28)-Exenatide 2022972-67-2 98%
    (D-Asp28)-Exenatide is an Exenatide (HY-13443) impurity. Exenatide is a long-acting glucagon-like peptide-1 receptor agonist.
    (D-Asp28)-Exenatide
  • HY-P4459
    (Des-Gly2)-Exenatide 1678416-78-8 98%
    (Des-Gly2)-Exenatide is a potential impurity of Exenatide (HY-13443).
    (Des-Gly2)-Exenatide
  • HY-P4492
    Suc-Phe-Leu-Phe-SBzl 80651-94-1 98%
    Suc-Phe-Leu-Phe-SBzl is a substrate of ATP-dependent protease.
    Suc-Phe-Leu-Phe-SBzl
  • HY-P4590
    (Glu20)-Glucagon (1-29) (human, rat, porcine) 2022956-46-1 98%
    (Glu20)-Glucagon (1-29) (human, rat, porcine) is the deamidation product of glucagon.
    (Glu20)-Glucagon (1-29) (human, rat, porcine)
Cat. No. Product Name / Synonyms Application Reactivity